James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Community Health Systems (CYH), Hospitals Aren’t Done Collapsing Yet

Don't go bottom-fishing with Community Health Systems (CYH) just yet. Thursday's meltdown is more complicated than it looks.

EBAY Stock Is a Buy After Earnings … Once It Settles

If investors are willing to wait for eBay stock to come back to earth after the post-earnings jump, it's not a bad (speculative) idea.

Why Yahoo! Inc. (YHOO), VMware, Inc. (VMW) and Valeant Pharmaceuticals Intl. Inc. (VRX) Are 3 of Today’s Worst Stocks

Yahoo! (YHOO), VMware (VMW) and Valeant Pharmaceuticals (VRX) led the bearish charge on Wednesday. Here's what investors need to know.

TSLA Stock – Did Consumer Reports Just Deliver a KO Punch?

Tesla Motors Inc (TSLA) stock plunged following news of an alarming assessment of the Model S, but there's a much bigger reason to be worried.

Biogen Stock Finally Has More Upside Than Downside

After a 30% beat-down just since June (and down 40% since March's peak), Biogen stock is a buy now that the company is streamlining.